NeoStem Inc Stock Nyse
Equities
NBS
US6406503051
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
05-20 | Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 23.93M 32.72M |
---|---|---|---|---|---|
Net income 2024 * | -25M -34.18M | Net income 2025 * | -30M -41.02M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.94
x | P/E ratio 2025 * |
-1.07
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.21% |
Latest transcript on NeoStem Inc
1st Jan change | Capi. | |
---|---|---|
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- LSTA Stock
- NBS Stock